Status: Recruiting
68Ga-B7-H3 Nanobody ImmunoPET in Osteosarcoma
This study aims to evaluate the safety, feasibility, and imaging performance of a novel 68Ga-labeled B7-H3 nanobody for immunoPET imaging in patients with osteosarcoma. Participants with suspected or histologically confirmed osteosarcoma will undergo 68Ga-B7-H3 nanobody PET/CT imaging according to the study protocol. Imaging findings will be compared with conventional imaging and, when available, histopathological results. The study will assess tracer biodistribution, tumor uptake, lesion detectability, and safety to determine the potential clinical value of B7-H3-targeted immunoPET for the diagnosis and evaluation of osteosarcoma.
Participants needed: 16
Trial details
Phase: Early Phase 1Age: 10-80Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Aug 19, 2026Locations: 1
Eligibility criteria
Age ≥10 years. [+3]
Pregnant or breastfeeding. [+3]